Phospho-CD19 (Y531) Antibody

說明書

中文名稱：

磷酸化-CD19 (Y531)兔多克隆抗體
貨號：

CSB-PA070286
規格：

￥1090
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P15391
基因名：

CD19
別名：

CD19; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12; CD antigen CD19
宿主：

Rabbit
反應種屬：

Human,Mouse,Monkey
免疫原：

Synthesized peptide derived from Human CD19 around the phosphorylation site of Y531.
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產品提供形式：

Liquid
應用范圍：

WB, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
ELISA	1:10000

Protocols：

Western Blotting (WB) Protocol
ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge.
基因功能參考文獻：
1. diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53. PMID: 28484276
2. The impairment of Bregs and CD19+/BTLA+ cells could play an important pathogenic role in multiple sclerosis (MS). PMID: 27412504
3. Inhibition of Akt signaling during ex vivo priming and expansion gives rise to CD19CAR T cell populations that display comparatively higher antitumor activity PMID: 28331616
4. CD19-specific triplebody SPM-1 mediated potent lysis of cancer-derived B cell lines and primary cells from patients with various B-lymphoid malignancies. PMID: 27825135
5. The increase in CD19+CD24+CD27+ Bregs was closely associated with fasting insulin secretion. PMID: 28440417
6. The preclinical activity, safety and PK profile support clinical investigation of MGD011 (MGD011 is a CD19 x CD3 DART bispecific protein )as a therapeutic candidate for the treatment of B-cell malignancies PMID: 27663593
7. this study shows that CD19 isoforms enable resistance to adoptive cellular immunotherapy PMID: 28441264
8. Anti-CD19-chimeric antigen receptors T cells synergistically exerted collaborative cytotoxicity against primary double-hit lymphoma cells with anti-CD38-chimeric antigen receptors T cells. PMID: 28595585
9. Two infants with relapsed, refractory B-cell acute lymphoblastic leukemia went into complete remission after being treated with CD19-targeting CAR T cells derived from an unmatched donor PMID: 28193774
10. These data provide proof-of-principle for the view that newly generated Ab-secreting cells can acquire a mature plasma cell phenotype that is accompanied by loss of CD19 expression at an early stage of differentiation and that aging is not an obligate requirement for a CD19(neg) state to be established. PMID: 28490574
11. Results indicate the strong efficacy of FLAG-tagged CD19 CAR-T cells in solid and hematological cancer models. PMID: 28410137
12. The histological observations suggested that the patients represent diverse cases of NHL like mature B-cell type, mature T-cell type and high grade diffuse B-cell type NHL. The findings indicate that patients with NHL may also be analyzed for status of PAX5, CD19 and ZAP70, and their transcriptional and post-translational variants for the differential diagnosis of NHL and therapy. PMID: 27748274
13. The frequencies of CD19+CD24hiCD38hi B-regulatory lymphocyte were significantly increased in children with beta-thalassemia. PMID: 26852663
14. a CD45+/CD19 - cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma. PMID: 25739938
15. CD19 is required for TLR9-induced B-cell activation. Hence CD19/PI3K/AKT/BTK is an essential axis integrating BCRs and TLR9 signaling in human B cells. PMID: 26478008
16. High anti-EBV IgG levels in Crohn's disease are associated with 5-aminosalicylic acid treatment, tonsillectomy, and decrease of CD19(+) cells. PMID: 25914477
17. We propose that CD81 enables the maturation of CD19 and its trafficking to the membrane by regulating the exit of CD19 from the ER to the pre-Golgi compartment PMID: 25739915
18. we outline our approach to nonviral gene transfer using the Sleeping Beauty system and the selective propagation of CD19-specific CAR(+) T cells on AaPCs PMID: 25591810
19. We demonstrate that this motif plays a role in the maturation and recycling of CD19 but in a CD81-independent manner. PMID: 26111452
20. Studies indicate that anti-CD19 and anti-CD33 bispecific antibodies showed anticancer activity. PMID: 25883042
21. The synaptic recruitment of lipid rafts is dependent on CD19-PI3K module and cytoskeleton remodeling molecules. PMID: 25979433
22. gene deficiency results in severe lung disease in French patient PMID: 24684239
23. propose a multilayer model of plasma cell (PC) memory in which CD19(+) and CD19(-) PC represent dynamic and static components, respectively, permitting both adaptation and stability of humoral immune protection PMID: 25573986
24. Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcgammaRIIb and CD19. PMID: 24828435
25. Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation. PMID: 24418477
26. A lower primary CD24(hi) CD27(+) CD19(+) B cells may be an immunologic aspect of new-onset SLE that may be a useful tool to evaluate lupus activity and monitor the response to therapy. PMID: 24286662
27. higher percentage of CD19+ cells in patients with acute appendicitis; decreases after appendectomy PMID: 24375063
28. CD20 and CD19 targeting vectors induce activating stimuli in resting B lymphocytes, which most likely renders them susceptible for lentiviral vector transduction. PMID: 24244415
29. Latently infected cells from patients with multiple sclerosis, treated with natalizumab, initiate differentiation to CD19+ cells that favor growth of JC polyomavirus. PMID: 24664166
30. This inhibitory function of FcgammaRIIB in impairing the spatial-temporal colocalization of BCR and CD19 microclusters in the B cell immunological synapse may help explain the hyper-reactive features of systemic lupus erythematosus PMID: 24790152
31. Considering that the CD19 complex regulates the events following antigen stimulation, the change in CD19 complex detected in transient hypogammaglobulinemia of infancy may be related to insufficiency of antibody production. PMID: 22820757
32. CD19 emerged as a powerful predictor of event-free and overall survival in CNS diffuse large B-cell lymphomas and Burkitt lymphomas PMID: 24501214
33. these data demonstrate that CD19 and CD32b differentially inhibit B cell expansion and plasma cell differentiation, depending on the nature of the activating stimuli, when engaged with monospecific Abs. PMID: 24442430
34. CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. PMID: 23193950
35. CD19 is expressed very early in B-cell development and is a good target for antibody therapy in lymphoblastic leukemia. PMID: 23277329
36. The resulting CD19(high)/CD19(low) B-cell ratio increased markedly in the milk-tolerant group. PMID: 22563781
37. Use of c-Myc transgenic mice deficient in CD19 expression leads to identification of a c-Myc:CD19 regulatory loop that positively influences B cell transformation and lymphoma progression. PMID: 22826319
38. Results obtained through a large cohort of European caucasian patients with systemic sclerosis do not support the contribution of CD19, CD20, CD22, CD24 variants to the genetic susceptibility. PMID: 21961844
39. Data indicate that among MDS cases, CD15+ and CD19+ cell TLs were positively correlated, and PBL TL was was not associated with hTERT genotype. PMID: 21635204
40. Studies showed the qualitative and quantitative expression of four target surface antigens, CD19, CD20, CD22, and CD33, for which MoAbs are currently available for clinical use, in ALL. PMID: 21348573
41. Data show that CD45+CD19- MCL-ICs play a role in the drug resistance of MCL, and this drug resistance was largely due to quiescent properties with enriched ABC transporters. PMID: 21599592
42. A missense mutation of CD19 in the conserved tryptophan 41 in immunoglobulin superfamily domain resulted in antibody deficiency. PMID: 21330302
43. Data suggest that CD19 and CD33 are present on the surface of the leukemic cell lines such that they can be connected by a single sctb molecule. PMID: 21081841
44. CD23 and CD19 are important factors that associated with serum total IgE in the pathogenesis of allergic rhinitis. PMID: 20359104
45. binding sites for CD19 and CD16 have a role in antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells PMID: 21339041
46. Heterozygous loss of CD19 causes some changes in the naive B-cell compartment, but overall in vivo B-cell maturation or humoral immunity is not affected. PMID: 20445561
47. Altered CD19/CD22 balance in Egyptian children and adolescents with systemic lupus erythematosus. PMID: 20726320
48. The CD27(+) B-cell population was found to highly express CXCR3 in chronic hepatitis C (CHC), thus suggesting that the CD27(+) B-cell population was recruited from peripheral blood to the inflammatory site of the liver of CHC. PMID: 20377416
49. Aberrant expression of CD19 in acute myeloblastic leukemia with t(8;21) involves a poised chromatin structure and PAX5. PMID: 20208555
50. Studies indicate taht B lymphocytes proliferated when approximately 100 antigen receptors per cell, 0.03 percent of the total, were coligated with CD19. PMID: 20164433
顯示更多

收起更多
相關疾病：

Immunodeficiency, common variable, 3 (CVID3)
亞細胞定位：

Cell membrane; Single-pass type I membrane protein. Membrane raft; Single-pass type I membrane protein.
組織特異性：

Detected on marginal zone and germinal center B cells in lymph nodes. Detected on blood B cells (at protein level).
數據庫鏈接：

HGNC: 1633

OMIM: 107265

KEGG: hsa:930

STRING: 9606.ENSP00000437940

UniGene: Hs.652262

Most popular with customers

XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human